AVID BIOSERVICES INC. - COMMON STOCK

Avid Bioservices to Participate in RBC Global CDMO Conference

27 Sep 2022 15:05:00 By Nasdaq GlobeNewswire

Avid Bioservices Appoints Michael Alston, Jr. as Vice President, Operations

22 Sep 2022 07:05:00 By Nasdaq GlobeNewswire

Avid Bioservices to Participate in Morgan Stanley 20th Annual Global Healthcare Conference

07 Sep 2022 15:05:00 By Nasdaq GlobeNewswire

Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2022 and Recent Developments

06 Sep 2022 15:05:00 By Nasdaq GlobeNewswire

Avid Bioservices Appoints Pramthesh (Prem) Patel, Ph.D., as Vice President, Process Development for Mammalian Cell Business

01 Sep 2022 07:05:00 By Nasdaq GlobeNewswire

Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2023 After Market Close on September 6, 2022

30 Aug 2022 15:05:00 By Nasdaq GlobeNewswire

Avid Bioservices Reports Financial Results for Fourth Quarter and Full Fiscal Year Ended April 30, 2022 and Recent Developments

29 Jun 2022 15:05:00 By Nasdaq GlobeNewswire

Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2022 After Market Close on June 29, 2022

22 Jun 2022 15:05:00 By Nasdaq GlobeNewswire

Avid Bioservices Announces Launch of Analytical and Process Development Suites Within New, World-Class Viral Vector Development and Manufacturing Facility

14 Jun 2022 07:05:00 By Nasdaq GlobeNewswire

Avid Bioservices Announces Further Expansion of Process Development Capacity for Mammalian Cell Business

13 Jun 2022 07:05:00 By Nasdaq GlobeNewswire

Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences & MedTech Forum

16 Mar 2022 15:05:00 By Nasdaq GlobeNewswire

Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2022 and Recent Developments

08 Mar 2022 15:09:16 By Nasdaq GlobeNewswire

Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2022 after Market Close on March 8, 2022

01 Mar 2022 15:05:01 By Nasdaq GlobeNewswire

Avid Bioservices Announces Official Opening of Second Downstream Processing Suite Within Myford North Facility

10 Jan 2022 07:05:00 By Nasdaq GlobeNewswire

Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2021 and Recent Developments

07 Dec 2021 15:05:00 By Nasdaq GlobeNewswire

Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2022 After Market Close on December 7, 2021

30 Nov 2021 15:05:00 By Nasdaq GlobeNewswire

Avid Bioservices Appoints Elie G. Hanania, Ph.D., as Vice President, Process Development, Viral Vector Technologies

04 Nov 2021 07:05:00 By Nasdaq GlobeNewswire

Avid Bioservices to Join S&P SmallCap 600 Index

26 Oct 2021 07:05:00 By Nasdaq GlobeNewswire

Avid Bioservices Announces Expansion into Viral Vector Development and Manufacturing Services for Cell and Gene Therapy

14 Oct 2021 07:05:00 By Nasdaq GlobeNewswire

Avid Bioservices Appoints Matthew Kwietniak as Chief Commercial Officer

07 Oct 2021 07:05:00 By Nasdaq GlobeNewswire